Mission Bio and SequMed Sign Collaboration Agreement Announcing Partnership to Provide Tapestri Services and Co-Develop Clinical Applications in China

On December 30, 2021 Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, reported that it has signed an agreement with SequMed, a pioneer in single-cell omics technology innovation and applications in China (Press release, Mission Bio, DEC 30, 2021, View Source [SID1234597860]). The agreement will allow Mission Bio to expand its product and services offerings into China, a key region of growth for its geographical expansion strategy, enabling high quality single-cell sequence services using Mission Bio’s products to customers in mainland China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this new and important collaboration, Mission Bio and SequMed will work jointly by integrating Mission Bio’s technology platform into SequMed’s clinical assay development and data analysis capabilities to co-develop novel single cell assays for early detection, medication guidance, and prognostic monitoring of cancers, as well as reproductive genetics applications. This partnership builds on Mission Bio’s commitment to providing high quality single-cell multi-omics with the Tapestri platform in China, where there is an increasing demand for single-cell innovation for clinical diagnosis.

"Tumor heterogeneity is always one of the biggest challenges for cancer therapy and the development of treatment resistance," said Yan Zhang, CEO of Mission Bio. "Our Tapestri single-cell sequencing solutions enable us to detect the co-occurring mutations within cancer cells, allowing us to understand the mechanisms of resistance at a granular level. We are excited to collaborate with SequMed. By integrating our single-cell technology with SequMed’s expertise in clinical assay development, we are committed to improving diagnosis, prognosis, and treatment of diseases in China."

Prof. Xinghua Victor Pan, Chairman of Technology Committee of SequMed, said, "We are dedicated to promoting the development and application of next-generation single-cell multi-omics technology in scientific and clinical research. We look forward to working with Mission Bio to develop novel single-cell assays for different diseases, from molecular mechanism elucidation to clinical medicine acceleration. With the synergies between the two collaborating parties, SequMed will enter into a new era, providing our customers in China with comprehensive solutions for personalized medicine."